About this Session
(Bio) Markers and milestones at the crossroads of mHSPC
Expert speakers provided a comprehensive overview of the latest advancements and challenges in the field, including the importance of early detection and screening.
Key topics covered
- The importance of age, comorbidities, and tumour biology to guide treatment decisions
- First-line androgen receptor pathway inhibitor (ARPi)-based therapy, and the possibility of PSA response as an early marker
- Outcomes for patients with metastatic hormone-sensitive prostate cancer and homologous recombination repair (HRR) alterations (CAPTURE study)
- Efficacy and safety results from the AMPLITUDE study, and the need for earlier genomic testing
Hear from the Experts
Dr. Miguel Ramírez-Backhaus
Dr. Miguel Ramírez-Backhaus discusses the value of real-world data, decision-making around doublets versus triplets, and the importance of shared decision making for patient outcomes.
Prof. Jozefina Casuscelli
Prof. Jozefina Casuscelli outlines barriers to overcome for biomarker-driven care, the combination of PSA dynamics with other key factors for fully informed treatment decisions, and the value of collaboration between healthcare professionals and with patients.
Prof. Gert Attard
Prof. Gert Attard explores the clinical implications of the CAPTURE and AMPLITUDE studies, the role of shared decision making to balance survival advantage with toxicity, and choosing the right treatment for the right patient.
Featured Prostate Cancer Events
Join our upcoming symposia and webinars hosted by our leading specialists. Registration for events and access to post-event recordings and materials are available exclusively for J&J Medical Cloud users.
13-16 March 2026
EAU 2026
London, United Kingdom
We are excited to be hosting our 2nd workshop on diversity in GU and a prostate cancer symposium at EAU 2026.
30 April-2 May 2026
APCCC 2026
Lugano, Switzerland
We are proud to be gold sponsors of the upcoming APCCC - a great opportunity for physicians to connect with leading experts from around the world.
23-27 October 2026
Join us at ESMO 2026 as we look forward to sharing insights and engaging in meaningful medical education - details to come
ESMO 2026
Madrid, Spain
Join us at ESMO 2026 as we look forward to sharing insights and engaging in meaningful medical education - details to come
Register or sign in for J&J Medical Cloud to unlock access to upcoming events, stay updated on the latest educational opportunities, and connect with a network of healthcare professionals.
Past Events
If you registered for a previous session but were unable to attend, you can log in to access recorded sessions and request materials. Please note that for some recordings and materials, the content may not be available in your country.
Expert Insights: The importance of early testing in metastatic prostate cancer (mPC) – filmed at ASCO 2025
Prof. Eleni Efstathiou, Prof. Gert Attard, Dr. Elena Castro, and Dr. Brigida Maiorano examine the latest trials and discuss the need for earlier testing in mPC to aid treatment decisions.
Expert Insights: New mechanisms of action in prostate cancer treatment – filmed at ASCO 2025
Dr. Joaquin Mateo, Dr. Andrew Parsonson, and Dr. Capucine Baldini discuss promising mechanisms of action in the prostate cancer space, including antibody-drug conjugates, bispecific antibodies, and combination therapies.
Johnson & Johnson’s Young Experts in Science (YES) Meeting
Our annual meeting – for those earlier in their career specialisation in prostate cancer – focuses on networking, interactive scientific discussions, and enhancing specific skills to improve patient care across the EMEA region by best practice sharing.
Register with J&J Medical Cloud to access our full education library, including recordings, slides, and new session announcements.
Stay in Touch
Contact us
To report an Adverse Event (medication side effect) or a Product Quality Complaint (an issue with one of our products), please select the appropriate link from the Contact dropdown menu. To submit a medical information request, choose the Medical Information page.
Abbreviations
ARPi, androgen receptor pathway inhibitor; GU, genitourinary; HRR, homologous recombinant repair; mHSPC, metastatic hormone-sensitive prostate cancer; PSA, prostate-specific antigen.
CP-540421 - December 2025
Janssen Pharmaceutica NV